Randomized, double-blinded, placebo-controlled trial of early administration of recombinant human granulocyte colony-stimulating factor to non-neutropenic preterm newborns between 33 and 36 weeks with presumed sepsis

Scandinavian Journal of Infectious Diseases

Volumn 34, Issue 12, 2002, Pages 893-897

  Küçüködük, Sükrü ^a   Sezer, Taner ^a   Yildiran, Alisan ^a   Albayrak, Davut ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE AGENT;

ARTICLE; CELL MATURATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GESTATIONAL AGE; HUMAN; LEUKOCYTE COUNT; MALE; NEUTROPENIA; NEUTROPHIL; NEWBORN; NEWBORN INTENSIVE CARE; PREMATURITY; SEPSIS; SERUM; THROMBOCYTE COUNT;

DOUBLE-BLIND METHOD; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMAN; INFANT, NEWBORN; INFANT, PREMATURE; INTENSIVE CARE UNITS, NEONATAL; NEUTROPENIA; SEPSIS; TIME FACTORS; TUMOR NECROSIS FACTOR;

EID: 0036989659     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/0036554021000026966     Document Type: Article

References (19)

1. Cairo MS. Therapeutic implications of dysregulated colony-stimulating factor expression in neonates. Blood 1993; 82: 2269-72.
2. Parravicini E, van de Ven C, Andersen L, Cairo MS. Transfus Med Rev 2002; 16: 11-24.
3. Bernstein HM, Pollock BH, Calhoun DA, Christensen RD. Administration of recombinant granulocyte colony-stimulating factor to neonates with septicemia: a meta-analysis. J Pediatr 2001; 138: 917-20.
4. Rook G. Immunity to bacteria and fungi. In: Roitt I, Brostoff J, Male D, eds. Immunology, 4th edn. London: Mosby, 1998: 17.1-17.13.
5. Ofek I, Sharon N. Lectinophagocytosis: a molecular mechanism of recognition between cell surface sugars and lectins in the phagocytosis of bacteria. Infect Immun 1988; 56: 539-47.
6. Miura E, Procianoy RS, Bittar C, Miura CS, Miura MS, Mello C, Christensen RD. A randomized, double-masked, placebo-controlled trial of recombinant granulocyte colony-stimulating factor administration to preterm infants with the clinical diagnosis of early-onset sepsis. Pediatrics 2001; 107: 30-5.
7. Gillan ER, Christensen RD, Suen Y, Ellis R, Van de Ven C, Cairo MS. A randomized, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor administration in newborn infants with presumed sepsis: significant induction of peripheral and bone marrow neutrophilia. Blood 1994; 84: 1427-33.
8. Schibler KR, Osborne KA, Leung LY, Le TV, Baker SI, Thompson DD. A randomized, placebo-controlled trial of granulocyte colony-stimulating factor administration to newborn infants with neutropenia and clinical signs of early-onset sepsis. Pediatrics 1998; 102: 6-13.
9. Drossou-Agakidou V, Kanakoudi-Tsakalidou F, Sarafidis K, Taparkou A, Tzimouli V, Tsandali H, Kremenopoulos G. Administration of recombinant human granulocyte-colony stimulating factor to septic neonates induces neutrophilia and enhances the neutrophil respiratory burst and beta2 integrin expression. Results of a randomized controlled trial. Eur J Pediatr 1998; 157: 583-8.
10. Manroe BL, Weinberg AG, Rosenfeld CR, Browne R. The neonatal blood count in health and disease. I. Reference values for neutrophilic cells. J Pediatr 1979; 95: 89-98.
11. Tollner U. Early diagnosis of septicemia in the newborn. Clinical studies and sepsis score. Eur J Pediatr 1982; 138: 331-7.
12. Goldman S, Ellis R, Dhar V, Cairo MS. Rationale and potential use of cytokines in the prevention and treatment of neonatal sepsis. Clin Perinatol 1998; 25: 699-710.
13. Bedford Russell AR, Emmerson AJB, Wilkinson N, Chant T, Sweet DG, Halliday HL, et al. A trial of recombinant human granulocyte colony stimulating factor for the treatment of very low birthweight infants with presumed sepsis and neutropenia. Arch Dis Child Fetal Neonatal Ed 2001; 84: F172-6.
14. Gorgen I, Hartung T, Leist M, Nierhorster M, Tiegs G, Uhlig S, Weitzel F, Wendel A. Granulocyte colony-stimulating factor treatment protects rodent against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor. J Immunol 1992; 149: 918-24.
15. Lundblad R, Nesland JM, Giercksky KE. Granulocyte colony-stimulating factor improves survival rate and reduces concentrations of bacteria, endotoxin, tumor necrosis factor, endothelin-1 in fulminate intra-abdominal sepsis in rats. Crit Care Med 1996; 24: 820-6.
16. Sirota L, Punsky I, Bessler H. Effect of indomethacin on IL-1β, IL-6 and TNFα production by mononuclear cells of preterm newborns and adults. Acta Paediatr 2000; 89: 331-5.
17. Gessler P, Kirchmann N, Kientsch-Engel R, Haas N, Lasch P, Kachel W. Serum concentrations of granulocyte colony-stimulating factor in healthy term and preterm neonates and in those with various diseases including bacterial infection. Blood 1993; 82: 3177-82.
18. Kennon C, Overturf G, Beisman S, Sierra E, Smith KJ, Brann B. Granulocyte colony-stimulating factor as a marker for bacterial infection in neonates. J Pediatr 1996; 128: 765-9.
19. Calhoun DA, Lunoe M, Du Y, Hutson AD, Veerman M, Christensen RD. Granulocyte colony-stimulating factor serum and urine concentrations in neutropenic neonates before and after the intravenous administration of recombinant granulocyte colony-stimulating factor. Pediatrics 2000; 105: 392-7.